Page last updated: 2024-11-10

zelandopam

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

zelandopam: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID3078105
CHEMBL ID2105532
SCHEMBL ID18311503
MeSH IDM0449618

Synonyms (16)

Synonym
(4s)-4-(3,4-dihydroxyphenyl)-1,2,3,4-tetrahydroisoquinoline-7,8-diol
(-)-(s)-4-(3,4-dihydroxyphenyl)-1,2,3,4-tetrahydro-7,8-isoquinolinediol
zelandopam [inn]
ir6xyd8sax ,
139233-53-7
7,8-isoquinolinediol, 4-(3,4-dihydroxyphenyl)-1,2,3,4-tetrahydro, (4s)
unii-ir6xyd8sax
zelandopam
selandopam
CHEMBL2105532
zelandopam [who-dd]
SCHEMBL18311503
zelandopam free base
(s)-4-(3,4-dihydroxyphenyl)-1,2,3,4-tetrahydroisoquinoline-7,8-diol
Q27280859
AKOS040749840

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" SCH23390 (3-30 nmol), a selective D1 receptor antagonist, caused a progressive parallel shift to the right of the dose-response curve for YM435-stimulated pancreatic secretion without changing the maximum response."( Effects of YM435, a novel dopamine D1 receptor agonist, on pancreatic exocrine secretion in anesthetized dogs.
Chiba, S; Iwatsuki, K; Ren, LM, 1992
)
0.28
" SCH23390 (3-30 nmol), a selective D-1 DA receptor antagonist, caused a progressive parallel shift to the right in the dose-response curve for DA-induced pancreatic secretion without changes in the maximal response."( D-1 dopamine receptors mediate dopamine-induced pancreatic exocrine secretion in anesthetized dogs.
Chiba, S; Horiuchi, A; Iwatsuki, K; Ren, LM, 1995
)
0.29
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (17)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's15 (88.24)18.2507
2000's2 (11.76)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.28

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.28 (24.57)
Research Supply Index2.89 (2.92)
Research Growth Index4.17 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.28)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (5.88%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other16 (94.12%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]